cubist pharmaceuticals

M&A in the biotech and pharmaceutical industries continues. Bristol-Myers Squibb (NYSE: BMY) just announced it has agreed to acquire Amylin Pharmaceuticals (NASDAQ: AMLN) for $5.3 billion. And Human Genome Sciences (NASDAQ: HGSI) has opened itself up to bidders, including GlaxoSmithKline (NYSE...

Watson Pharmaceuticals (NYSE: WPI) is scheduled to report its second-quarter 2011 results Tuesday, July 26, before the markets open. Strong first-quarter results pushed the share price to a new all-time high; can second-quarter results do the same? Analysts are looking for the drug maker to report...

Jefferies published a report on Cubist Pharmaceuticals (NASDAQ: CBST) that increased fiscal year guidance. In the research report, Jefferies wrote, "In 2Q11, U.S. Cubicin sales of $169M (~10% q/q) came in above our/cons estimates of $162M/$165M, respectively; slightly lower ex-U.S. Cubicin revenue...

Bank of America reiterated its Neutral rating on Cubist Pharmaceuticals (NASDAQ: CBST). In a research report published today, Bank of America states, "We rate CBST shares Neutral and believe the stock is mostly fairly valued. A major overhang was recently lifted when Cubist settled its Cubicin...

Jefferies is out with its report today on Cubist Pharmaceuticals (NASDAQ: CBST), raising its PT from $36 to $44. In a note to clients, Jefferies writes, "CBST's CXA-201 is potentially the most potent Gram-negative antibiotic in development (Phase 3 to begin by YE11), particularly for the most...

Jefferies & Company has raised the price target on Cubist Pharmaceuticals (NASDAQ: CBST) from $36 to $44 and maintains its Buy rating.

Global Hunter Securities has initiated coverage on Cubist Pharmaceuticals (NASDAQ: CBST) with a Neutral rating and no price target.

Oppenheimer, which upgraded shares of Cubist Pharmaceuticals Inc. (NASDAQ: CBST), is providing some color on the stock. “We view the recent settlement with Teva Pharmaceuticals (NASDAQ: TEVA) regarding generic Cubicin as highly favorable for CBST, providing visibility into the Cubicin franchise,”...

Oppenheimer has upgraded Cubist Pharmaceuticals (NASDAQ: CBST) from Perform to Outperform and has established a $37 price target.

Oppenheimer is out with its report today on Cubist Pharmaceuticals (NASDAQ: CBST), maintaining Perform. In a note to clients, Oppenheimer writes, "CBST's primary product, Cubicin, is an intravenously administered antibiotic, which we estimate will bring in $614M of revenue in 2010. We expect...

According to Jefferies, Cubist Pharmaceuticals (NASDAQ: CBST) delivers ~3-6% higher U.S. Cubicin sales of $154M in the seasonally weak/uneventful first quarter of the year. Jefferies reported that this is in-line GAAP EPS of $0.34 (vs. its/cons estimates of $0.35/$0.30). “Our $36 PT is based on U....

Lazard Capital Markets has upgraded Cubist Pharmaceuticals (NASDAQ: CBST) from Hold to Buy and has established a $33 price target following the settlement of patent litigation with Teva Pharmaceuticals (NASDAQ: TEVA).

Needham has raised the price target on Cubist Pharmaceuticals (NASDAQ: CBST) from $27 to $33 and following the company's settlement with Teva (NASDAQ: TEVA). Buy rating maintained.

Wedbush Securities has raised the price target on Cubist Pharmaceuticals (NASDAQ: CBST) from $25 to $32 and maintains its Outperform rating.